Details of the Drug

General Information of Drug (ID: DMUJ1WV)

Drug Name
Tebentafusp
Synonyms IMCgp100
Indication
Disease Entry ICD 11 Status REF
Gastric cancer 2B72 Approved [1]
Cutaneous melanoma 2C30 Phase 2 [2]
Melanoma 2C30 Phase 2 [3]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0S0BJ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocytes lineage-specific antigen GP100 (PMEL) TT8MK59 PMEL_HUMAN Modulator [4]
T-cell receptor (TCR) TT7AKW1 NOUNIPROTAC Modulator [5]
T-cell surface glycoprotein CD3 gamma (CD3G) TTV3XPL CD3G_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
4 Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)